Bruce Coate

665 total citations
25 papers, 355 citations indexed

About

Bruce Coate is a scholar working on Neurology, Psychiatry and Mental health and Infectious Diseases. According to data from OpenAlex, Bruce Coate has authored 25 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Neurology, 10 papers in Psychiatry and Mental health and 7 papers in Infectious Diseases. Recurrent topics in Bruce Coate's work include Parkinson's Disease Mechanisms and Treatments (11 papers), Attention Deficit Hyperactivity Disorder (9 papers) and HIV/AIDS drug development and treatment (7 papers). Bruce Coate is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (11 papers), Attention Deficit Hyperactivity Disorder (9 papers) and HIV/AIDS drug development and treatment (7 papers). Bruce Coate collaborates with scholars based in United States, United Kingdom and Belgium. Bruce Coate's co-authors include Clive Ballard, Joseph Mrus, Robert J. Ryan, Srdjan Stankovic, Stuart Isaacson, Thomas N. Kakuda, Victor Abler, David Anderson, James M. Youakim and James C. Norton and has published in prestigious journals such as Hepatology, Neurology and Journal of Hepatology.

In The Last Decade

Bruce Coate

23 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bruce Coate United States	13	120	106	76	65	46	25	355
Pauls Aldiņš United Kingdom	6	42 0.3×	118 1.1×	18 0.2×	83 1.3×	53 1.2×	7	290
Antonia Wadley South Africa	15	149 1.2×	85 0.8×	30 0.4×	79 1.2×	161 3.5×	30	450
Karl Farcnik Canada	9	48 0.4×	21 0.2×	96 1.3×	130 2.0×	17 0.4×	11	331
Scott L. Letendre United States	13	26 0.2×	270 2.5×	68 0.9×	130 2.0×	391 8.5×	32	656
Joseph J. Rasimas United States	17	34 0.3×	30 0.3×	154 2.0×	41 0.6×	7 0.2×	30	623
W Lowenstein France	13	17 0.1×	65 0.6×	35 0.5×	133 2.0×	87 1.9×	49	596
Johnathan A. Edwards United States	8	113 0.9×	128 1.2×	13 0.2×	16 0.2×	18 0.4×	21	357
Paulien R. Wermeling Netherlands	7	31 0.3×	93 0.9×	122 1.6×	125 1.9×	14 0.3×	10	417
Stephen Ramage United Kingdom	5	21 0.2×	127 1.2×	16 0.2×	83 1.3×	329 7.2×	7	489
Terry Alexander United States	11	57 0.5×	222 2.1×	40 0.5×	71 1.1×	278 6.0×	11	470

Countries citing papers authored by Bruce Coate

Since Specialization

Citations

This map shows the geographic impact of Bruce Coate's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Coate with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Coate more than expected).

Fields of papers citing papers by Bruce Coate

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce Coate. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Coate. The network helps show where Bruce Coate may publish in the future.

Co-authorship network of co-authors of Bruce Coate

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce Coate. A scholar is included among the top collaborators of Bruce Coate based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce Coate. Bruce Coate is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alva, Gus, et al.. (2024). Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study. Journal of Alzheimer s Disease. 98(1). 265–274. 5 indexed citations

Alva, Gustavo, et al.. (2023). Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease‐related neuropsychiatric symptoms: a Phase 3b study. Alzheimer s & Dementia. 19(S21). 1 indexed citations

Abler, Victor, et al.. (2022). Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis. Frontiers in Neurology. 13. 919778–919778. 5 indexed citations

Isaacson, Stuart, Clive Ballard, Bruce Coate, et al.. (2021). Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients. Parkinsonism & Related Disorders. 87. 25–31. 14 indexed citations

Ballard, Clive, Erin P. Foff, Pierre N. Tariot, et al.. (2021). Impact of pimavanserin on cognitive measures in patients with neurodegenerative disease (NDD): results from 4 placebo-controlled clinical studies (2369). Neurology. 96(15_supplement). 1 indexed citations

Alva, Gustavo, Jason Aldred, Bruce Coate, et al.. (2020). An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression. Journal of Parkinson s Disease. 10(4). 1751–1761. 13 indexed citations

Isaacson, Stuart, Bruce Coate, James J. S. Norton, & Srdjan Stankovic. (2020). Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis. Journal of Parkinson s Disease. 10(4). 1389–1396. 10 indexed citations

Ballard, Clive, James M. Youakim, Bruce Coate, & Srdjan Stankovic. (2019). Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. The Journal of Prevention of Alzheimer s Disease. 6(1). 27–33. 29 indexed citations

Espay, Alberto J., James C. Norton, Bruce Coate, et al.. (2018). Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications. Movement Disorders. 33(11). 1769–1776. 37 indexed citations

10.

Weintraub, Daniel, James J. S. Norton, Bruce Coate, et al.. (2018). 122 Use of Pimavanserin in Patients With Parkinson’s Disease Psychosis: Subgroup Analysis of Efficacy and Safety in Patients With and Without Cognitive Impairment. CNS Spectrums. 23(1). 77–77. 3 indexed citations

11.

Overton, Edgar T., Pablo Tebas, Bruce Coate, et al.. (2016). Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clinical Trials. 17(2). 72–77. 13 indexed citations

12.

Ballard, Clive, Stuart Isaacson, Roger Mills, et al.. (2015). Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. Journal of the American Medical Directors Association. 16(10). 898.e1–898.e7. 49 indexed citations

13.

Brinson, Cynthia, Moti Ramgopal, Robert J. Ryan, et al.. (2015). The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects. HIV Medicine. 16(5). 288–296. 13 indexed citations

14.

Ryan, Robert J., et al.. (2014). Outcomes in Older Versus Younger Patients Over 96 Weeks in HIV-1– Infected Patients Treated with Rilpivirine or Efavirenz in ECHO and THRIVE. Current HIV Research. 11(7). 570–575. 9 indexed citations

15.

Zeuzem, Stefan, Ralph DeMasi, Bruce Coate, et al.. (2014). Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients. Journal of Hepatology. 60(6). 1112–1117. 19 indexed citations

16.

Wright, Rodney, Bryan Baugh, Kimberley Brown, et al.. (2013). Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Medicine. 15(1). 50–56. 41 indexed citations

17.

Younossi, Zobair M., Francesco Negro, Lawrence Serfaty, et al.. (2013). Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology. 58(6). 1897–1906. 22 indexed citations

18.

Anderson, David, et al.. (2012). Week 96 Outcomes of Patients With Less Treatment Experience Versus More Treatment Experience Receiving Etravirine in the DUET Trials. Current HIV Research. 10(3). 256–261. 2 indexed citations

19.

Kakuda, Thomas N., Vanitha Sekar, Peter Vis, et al.. (2012). Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Research and Treatment. 2012. 1–10. 28 indexed citations

20.

Zorrilla, C., Rodney Wright, Olayemi Osiyemi, et al.. (2012). Total and unbound darunavir (DRV) pharmacokinetics (PK) in HIV‐1‐infected pregnant women. Journal of the International AIDS Society. 15(S4). 1–2. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact